Return to CBI Antibody Core Home Page
  Return to human list
    Return to human ( Homo sapiens ) list


human ( Homo sapiens )
NOD2 (CARD15)



Western result: +
GST
GST-NOD2 (CARD15)
(fragment)

N.A. kDa (recombinant)
The western blot contains a test lane of ~20ug of a total protein extract from E coli with ~50ng to 500ng of the antigen (GST-antigen fusion protein). The negative control lane is the same except it contains ~50ng to 100 ng of a GST fusion protein of an irrelevant antigen. The blot was probed with a final antisera dilution of 1:1,000. The secondary antibody (Rabbit anti-mouse IgG + IgM, (H+L) horseradish peroxidase conjugated (Pierce)) is used at 1:5,000 dilution. Note, the molecular weight of the band on the western blot does not correspond to the molecular weight of the natural protein because only a fragment of the gene is used and it is fused to GST.

Antibody Name/Abbreviation: NOD2 (CARD15)
CBI Antibody Core Code: A0239

"Lot" Number: 2 Position: 100(82-181)
% Identical Homology of Target to Mouse Protein: 70% (NP_665856.1| caspase recruitment domain family, member 15)
Molecular Weight of fusion protein: N.A. KDa

Target sequence used to make this antibody:
SHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLHG
CWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERGF
VSQYECDEIRLPIFTPSQRA






Sequence Name: NOD2 (CARD15)
Full name: (or CARD15) caspase recruiment domain family, member 15
UniGene Number: N.A.
Accession Number: NM_022162
Source organism: human ( Homo sapiens )
Full length size (aa): 1040
NCBI information page: click here

Full length sequence:
MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQLVELLVSGSL
EGFESVLDWLLSWEVLSWEDYEGFHLLGQPLSHLARRLLDTVWNKGTWAC
QKLIAAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVE
NMLDLAWERGFVSQYECDEIRLPIFTPSQRARRLLDLATVKANGLAAFLL
QHVQELPVPLALPLEAATCKKYMAKLRTTVSAQSRFLSTYDGAETLCLED
IYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGE
AGSGKSTLLQRLHLLWAAGQDFQEFLFVFPFSCRQLQCMAKPLSVRTLLF
EHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDP
TSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQ
GIELYLRKRHHEPGVADRLIRLLQETSALHGLCHLPVFSWMVSKCHQELL
LQEGGSPKTTTDMYLLILQHFLLHATPPDSASQGLGPSLLRGRLPTLLHL
GRLALWGLGMCCYVFSAQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLE
FLHITFQCFFAAFYLALSADVPPALLRHLFNCGRPGNSPMARLLPTMCIQ
ASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKAL
LRRQACARWCLARSLRKHFHSIPPAAPGEAKSVHAMPGFIWLIRSLYEMQ
EERLARKAARGLNVGHLKLTFCSVGPTECAALAFVLQHLRRPVALQLDYN
SVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLAL
FNNKLTDGCAHSMAKLLACRQNFLALRLGNNYITAAGAQVLAEGLRGNTS
LQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALM
LAKNVMLEELCLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGA
EALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL





Questions? Click here for answers.


© Monday, February 16, 2009 by the CBI Antibody Core and the Center for Biomedical Inventions, University of Texas Southwestern Medical School.